"Antibodies, Bispecific" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
| Descriptor ID |
D018033
|
| MeSH Number(s) |
D12.776.124.486.485.114.125 D12.776.124.790.651.114.134 D12.776.377.715.548.114.134
|
| Concept/Terms |
Antibodies, Bispecific- Antibodies, Bispecific
- Bispecific Antibodies
- Bifunctional Antibodies
- Antibodies, Bifunctional
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Bispecific".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Bispecific".
This graph shows the total number of publications written about "Antibodies, Bispecific" by people in this website by year, and whether "Antibodies, Bispecific" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 4 | 0 | 4 |
| 2022 | 4 | 0 | 4 |
| 2023 | 4 | 0 | 4 |
| 2024 | 6 | 2 | 8 |
| 2025 | 7 | 1 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Bispecific" by people in Profiles.
-
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors. Cancer Res Commun. 2025 Sep 01; 5(9):1574-1583.
-
Blinatumomab use in pediatric B-ALL: where are we now? Blood Adv. 2025 Aug 12; 9(15):3946-3954.
-
Blinatumomab Administration in Pediatric B-Lineage ALL: Expert Recommendations From the Children's Oncology Group. Clin J Oncol Nurs. 2025 Aug 04; 29(4):303-312.
-
Caregiving for Children With Acute Lymphoblastic Leukemia Receiving Home-Based Blinatumomab: Caregiver Experiences and Recommendations. Pediatr Blood Cancer. 2025 Oct; 72(10):e31913.
-
Navigating B-ALL in the Era of Blinatumomab. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e472778.
-
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study. Blood. 2025 Apr 03; 145(14):1498-1509.
-
A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions. Pharmacoeconomics. 2025 Jul; 43(7):765-778.
-
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer. 2025 Mar; 6(3):528-539.
-
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Adv. 2025 Feb 25; 9(4):696-703.
-
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after =2 prior therapies. Blood. 2025 Feb 13; 145(7):708-719.